BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 19952801)

  • 21. Point: Clinical stage IA non-small cell lung cancer determined by computed tomography and positron emission tomography is frequently not pathologic IA non-small cell lung cancer: the problem of understaging.
    Stiles BM; Servais EL; Lee PC; Port JL; Paul S; Altorki NK
    J Thorac Cardiovasc Surg; 2009 Jan; 137(1):13-9. PubMed ID: 19154893
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Relationship between non-small cell lung cancer FDG uptake at PET, tumor histology, and Ki-67 proliferation index.
    Vesselle H; Salskov A; Turcotte E; Wiens L; Schmidt R; Jordan CD; Vallières E; Wood DE
    J Thorac Oncol; 2008 Sep; 3(9):971-8. PubMed ID: 18758298
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of demographic characteristics, surgical resection patterns, and survival outcomes for veterans and nonveterans with non-small cell lung cancer in the Pacific Northwest.
    Zeliadt SB; Sekaran NK; Hu EY; Slatore CC; Au DH; Backhus L; Wu DY; Crawford J; Lyman GH; Dale DC
    J Thorac Oncol; 2011 Oct; 6(10):1726-32. PubMed ID: 21857253
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic value of 18F-FDG uptake on positron emission tomography in patients with pathologic stage I non-small cell lung cancer.
    Um SW; Kim H; Koh WJ; Suh GY; Chung MP; Kwon OJ; Choi JY; Han J; Lee KS; Kim J
    J Thorac Oncol; 2009 Nov; 4(11):1331-6. PubMed ID: 19701106
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Results of surgical intervention for p-stage IIIA (N2) non-small cell lung cancer: acceptable prognosis predicted by complete resection in patients with single N2 disease with primary tumor in the upper lobe.
    Inoue M; Sawabata N; Takeda S; Ohta M; Ohno Y; Maeda H
    J Thorac Cardiovasc Surg; 2004 Apr; 127(4):1100-6. PubMed ID: 15052208
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic value of fluorine-18 fluorodeoxyglucose positron emission tomography imaging in patients with advanced-stage non-small-cell lung carcinoma.
    Hoang JK; Hoagland LF; Coleman RE; Coan AD; Herndon JE; Patz EF
    J Clin Oncol; 2008 Mar; 26(9):1459-64. PubMed ID: 18349396
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Stage migration, selection bias, and survival associated with the adoption of positron emission tomography among medicare beneficiaries with non-small-cell lung cancer, 1998-2003.
    Dinan MA; Curtis LH; Carpenter WR; Biddle AK; Abernethy AP; Patz EF; Schulman KA; Weinberger M
    J Clin Oncol; 2012 Aug; 30(22):2725-30. PubMed ID: 22753917
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Relationship between primary lesion FDG uptake and clinical stage at PET-CT for non-small cell lung cancer patients: An observation.
    Li M; Sun Y; Liu Y; Han A; Zhao S; Ma L; Zheng J; Yu J
    Lung Cancer; 2010 Jun; 68(3):394-7. PubMed ID: 19683358
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diagnostic and prognostic values of FDG-PET in patients with non-small cell lung cancer.
    Abe K; Baba S; Kaneko K; Isoda T; Yabuuchi H; Sasaki M; Sakai S; Yoshino I; Honda H
    Clin Imaging; 2009; 33(2):90-5. PubMed ID: 19237050
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 11C-Acetate can be used in place of 18F-fluorodeoxyglucose for positron emission tomography imaging of non-small cell lung cancer with higher sensitivity for well-differentiated adenocarcinoma.
    Nomori H; Shibata H; Uno K; Iyama K; Honda Y; Nakashima R; Sakaguchi K; Goya T; Takanami I; Koizumi K; Suzuki T; Kaji M; Horio H
    J Thorac Oncol; 2008 Dec; 3(12):1427-32. PubMed ID: 19057268
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Improvement of non-small-cell lung cancer staging by means of positron emission tomography.
    Albes JM; Lietzenmayer R; Schott U; Schülen E; Wehrmann M; Ziemer G
    Thorac Cardiovasc Surg; 1999 Feb; 47(1):42-7. PubMed ID: 10218620
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Etiology of solitary extrapulmonary positron emission tomography and computed tomography findings in patients with lung cancer.
    Lardinois D; Weder W; Roudas M; von Schulthess GK; Tutic M; Moch H; Stahel RA; Steinert HC
    J Clin Oncol; 2005 Oct; 23(28):6846-53. PubMed ID: 16192576
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of clinical and surgical-pathological staging in IIIA non-small cell lung cancer patients.
    Muehling B; Wehrmann C; Oberhuber A; Schelzig H; Barth T; Orend KH
    Ann Surg Oncol; 2012 Jan; 19(1):89-93. PubMed ID: 21755379
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Non-small cell lung cancer: FDG PET for nodal staging in patients with stage I disease.
    Farrell MA; McAdams HP; Herndon JE; Patz EF
    Radiology; 2000 Jun; 215(3):886-90. PubMed ID: 10831716
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Value of 18F-FDG PET in clinical staging of non-small-cell lung cancer].
    Liu SW; Yu JM; Xing LG
    Zhonghua Zhong Liu Za Zhi; 2004 Oct; 26(10):626-9. PubMed ID: 15634527
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients.
    Kanzaki R; Higashiyama M; Maeda J; Okami J; Hosoki T; Hasegawa Y; Takami M; Kodama K
    Interact Cardiovasc Thorac Surg; 2010 Jun; 10(6):1009-14. PubMed ID: 20197344
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Risk factor analysis of mediastinal lymph node metastasis in non-small cell lung cancer patients and the strategy of mediastinoscopy prior to surgery].
    Wang X; Zheng L; Zhang SY; Xie ZM; Yu H; Su XD; Wang JY; Huang ZF; Yang MT; Rong TH
    Zhonghua Zhong Liu Za Zhi; 2009 Jun; 31(6):456-9. PubMed ID: 19950559
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The maximum standardized uptake values on positron emission tomography of a non-small cell lung cancer predict stage, recurrence, and survival.
    Cerfolio RJ; Bryant AS; Ohja B; Bartolucci AA
    J Thorac Cardiovasc Surg; 2005 Jul; 130(1):151-9. PubMed ID: 15999056
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic value of SUVmax and metabolic tumor volume on 18F-FDG PET/CT in early stage non-small cell lung cancer patients without LN metastasis.
    Yoo IeR; Chung SK; Park HL; Choi WH; Kim YK; Lee KY; Wang YP
    Biomed Mater Eng; 2014; 24(6):3091-103. PubMed ID: 25227018
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Japanese Lung Cancer Registry Study: first prospective enrollment of a large number of surgical and nonsurgical cases in 2002.
    Sawabata N; Asamura H; Goya T; Mori M; Nakanishi Y; Eguchi K; Koshiishi Y; Okumura M; Miyaoka E; Fujii Y;
    J Thorac Oncol; 2010 Sep; 5(9):1369-75. PubMed ID: 20683209
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.